Latest news with #CitizensJMP
Yahoo
4 days ago
- Business
- Yahoo
Meta Platforms (META) Touts AI Skills as Key to Wage Growth, Eyes Bigger Role in Workforce Transformation
We recently published a list of . In this article, we are going to take a look at where Meta Platforms, Inc. (NASDAQ:META) stands against other AI stocks on Wall Street's radar. On June 2nd, Citizens JMP analyst Andrew Boone reiterated a Market Outperform rating on Meta Platforms, Inc. (NASDAQ:META) with a $750.00 price target. The analysts pointed out the importance of artificial intelligence (AI) skills in the workforce, citing Meta's claim that workers having AI-related skills could help boost their wages by as much as 20%. This claim highlights the value of developing AI competencies among employees. Photo by Alexander Shatov on Unsplash Drawing a comparison with trends noted in platforms such as Upwork, it was revealed that freelancers engaging in AI-related tasks on the platform earn 44% more than those who do not. This data point further signifies the importance of artificial intelligence skills, particularly in the gig economy. The firm further highlighted how Meta's focus on AI skills and impact on wage growth highlights how Meta remains committed to advancing AI in its business strategy. It is highly confident in the company's potential for growth as it ramps up the use of the said technology. Meta Platforms, Inc. (NASDAQ:META) is a global technology company. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
7 days ago
- Business
- Yahoo
Jim Cramer and Wall Street Are Watching Churchill Downs Incorporated (CHDN)
We recently published a list of . In this article, we are going to take a look at where Churchill Downs Incorporated (NASDAQ:CHDN) stands against other stocks on Jim Cramer and Wall Street's radar. Toward the end of April, Cramer called Churchill Downs Incorporated (NASDAQ:CHDN) a 'one-trick pony,' as he said: 'Oh, you know what, that's kind of, hey, it's a one-trick pony. I'm not a fan, but I am a fan of yours.' A city skyline looking down on a busy racetrack with jockeys on horseback. Churchill Downs Incorporated (NASDAQ:CHDN) provides racing entertainment, online wagering, and casino gaming, including horse racing events, sports betting, and gaming at its properties. The company also offers technology and data services for wagering platforms and race operations. On May 27, Citizens JMP cut its price target on Churchill Downs (NASDAQ:CHDN) to $138 from $144 and maintained an Outperform rating. The analyst noted that the company removed its historical racing machines in Louisiana, which were expected to generate $10 to $15 million in annual EBITDA. The firm added that efforts are in progress to recover the lost income. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails
On May 27, Citizens JMP lowered the firm's price target on Prothena Corporation plc (NASDAQ:PRTA) to $29 from $78 but kept an Outperform rating on the shares. The notable price target decrease came after Prothena Corporation plc (NASDAQ:PRTA) announced negative results from the Phase 3 AFFIRM-AL trial for birtamimab in AL amyloidosis on May 23. The trial missed the primary and secondary endpoints, which is why the company plans to discontinue it. A biopharmaceutical facility with technicians working on a manufacturing line of treatments and preventions. The analyst told investors in a research note that substantial cost-reducing initiatives are expected to follow the discontinuation of the AFFIRM-AL trial, including a considerable workforce reduction. Citizens JMP also announced plans to remove birtamimab from its model. However, the firm is bullish on Prothena Corporation plc (NASDAQ:PRTA), primarily due to the potential success of PRX012, its anti-Abeta immunotherapy for Alzheimer's disease. Prothena Corporation (NASDAQ:PRTA) is a clinical-stage neuroscience company that discovers and develops novel therapies for serious diseases. Its clinical pipeline includes both partnered and wholly owned therapies for AL amyloidosis, Alzheimer's disease, ATTR amyloidosis, Parkinson's disease, and other neurodegenerative diseases. While we acknowledge the potential of PRTA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PRTA and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT
In a report released on May 27, Jason Butler from Citizens JMP reiterated a Buy rating on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) with a price target of $19.00. Its fiscal Q1 2025 results, reported on May 15, showed positive operations, with net revenue reaching $20.4 million, driven by product net revenue of $17.2 million. The company beat earnings expectations with a reported EPS of $-0.06, which exceeded the expected $-0.21. A scientist in a lab coat with a microscope magnifying a sample of a rare disease therapy. Zevra Therapeutics, Inc. (NASDAQ:ZVRA) announced the closing of the sale of its Pediatric Rare Disease Priority Review Voucher (PRV) on April 7 to an undisclosed buyer, supporting the optimistic sentiment for the stock with gross proceeds of $150 million. The proceeds position the company to strengthen its balance sheet and support development programs and commercial launches. Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is a commercial-stage company that develops therapies for rare diseases with limited or no treatment options. Its product portfolio focuses on rare neurological and sleep conditions, including Idiopathic Hypersomnia, Urea Cycle Disorders, and Niemann-Pick disease type C. While we acknowledge the potential of ZVRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZVRA and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
27-05-2025
- Business
- Business Insider
Citizens JMP Sticks to Their Buy Rating for Cidara Therapeutics (CDTX)
In a report released today, Roy Buchanan from Citizens JMP maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report), with a price target of $47.00. The company's shares closed last Friday at $24.28. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Buchanan covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Inovio Pharmaceuticals, and Arbutus Biopharma. According to TipRanks, Buchanan has an average return of -26.6% and a 26.50% success rate on recommended stocks. Currently, the analyst consensus on Cidara Therapeutics is a Strong Buy with an average price target of $40.40, a 66.39% upside from current levels. In a report released on May 23, Needham also maintained a Buy rating on the stock with a $35.00 price target.
